Compare · JNJ vs REPH
JNJ vs REPH
Side-by-side comparison of Johnson & Johnson (JNJ) and Recro Pharma Inc. (REPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and REPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $558.86B, about 8091.0x REPH ($69.1M).
- JNJ has hit the wire 8 times in the past 4 weeks while REPH has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 1 for REPH).
- Company
- Johnson & Johnson
- Recro Pharma Inc.
- Price
- $232.15-0.24%
- $2.05-3.30%
- Market cap
- $558.86B
- $69.1M
- 1M return
- +4.36%
- -
- 1Y return
- +49.56%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 1
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Recro Pharma Inc.
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.
Latest JNJ
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
Latest REPH
- SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)
- SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)
- Lake Ryan David covered exercise/tax liability with 1,022 shares, decreasing direct ownership by 0.13% to 800,557 units (SEC Form 4)
- Enloe J David Jr was granted 196,474 shares, increasing direct ownership by 18% to 1,295,414 units (SEC Form 4)
- Lake Ryan David was granted 110,025 shares and covered exercise/tax liability with 37,453 shares, increasing direct ownership by 10% to 801,579 units (SEC Form 4)
- Lake Ryan David covered exercise/tax liability with 34,096 shares, decreasing direct ownership by 4% to 729,007 units (SEC Form 4)
- Lake Ryan David covered exercise/tax liability with 1,419 shares, decreasing direct ownership by 0.19% to 763,103 units (SEC Form 4)
- Lake Ryan David covered exercise/tax liability with 5,690 shares, decreasing direct ownership by 0.74% to 764,522 units (SEC Form 4)
- Lake Ryan David covered exercise/tax liability with 1,197 shares, decreasing direct ownership by 0.16% to 770,212 units (SEC Form 4)
- Recro Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits